糖尿病CLTI患者膝下旁路术:替代移植物选择
基于Vascular Quality Initiative数据库2010-2023年数据,回顾性分析17,701例因CLTI行膝下旁路术的糖尿病患者,比较自体大隐静脉(GSV)、自体臂静脉(AAV)和冷冻保存静脉(cryovein)的结局。AAV与GSV在无截肢生存率和免于主要肢体不良事件方面相当,而cryovein的围手术期移植物闭塞、大截肢及5年无截肢生存率均劣于GSV,但多因素回归显示cryovein仍独立增加截肢或死亡风险。
要点
- AAV可作为糖尿病CLTI患者膝下旁路术中GSV的有效替代移植物
- cryovein的围手术期移植物闭塞率(3.8% vs 1.5%)和大截肢率(4.1% vs 1.9%)显著高于GSV
- cryovein的5年无截肢生存率(55.8% vs 70.4%)和免于MALE率(55.0% vs 68.4%)均劣于GSV
核心结论
- AAV是糖尿病CLTI患者膝下旁路术中GSV的有效替代移植物。
- cryovein的结局劣于GSV,但在无其他移植物选择时仍可提供可接受的保肢效果。
研究设计与样本
- 回顾性查询前瞻性收集的Vascular Quality Initiative数据库,纳入2010-2023年因CLTI行膝下旁路术的糖尿病患者。
- 共纳入17,701例患者,按移植物类型分为GSV组(87.0%,n=15,393)、AAV组(3.5%,n=616)和cryovein组(9.6%,n=1,692)。
- 主要结局为无截肢生存率,次要结局为免于指数肢体再干预和免于主要肢体不良事件(MALE)。
主要发现
- AAV组与GSV组围手术期死亡率和早期血栓形成无差异。
- cryovein组围手术期移植物闭塞率(3.8% vs 1.5%;P < .001)和大截肢率(4.1% vs 1.9%;P < .001)显著高于GSV组,死亡率无差异。
- 5年无截肢生存率:cryovein组55.8% vs GSV组70.4%(P < .001);AAV组69.0% vs GSV组70.4%(P = .9)。
- 5年免于MALE率:AAV组66.4% vs GSV组68.4%(P = .5);cryovein组55.0% vs GSV组68.4%(P < .001)。
- 多因素回归分析显示,cryovein与截肢或死亡风险增加独立相关(HR 1.64;95%CI 1.4-1.8),AAV无差异(HR 0.91;95%CI 0.7-1.1)。
临床怎么用
- 在糖尿病CLTI患者需行膝下旁路术时,AAV可作为GSV的有效替代移植物。
- cryovein应优先用于无其他移植物选择的患者,因其结局劣于GSV但仍可保肢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic limb-threatening ischemia (CLTI) patients with diabetes mellitus (DM) have increased risk for major amputation despite surgical revascularization. As demonstrated in BEST-CLI (Best Surgery versus Best Endovascular Therapy in Critical Limb Ischemia), autologous great saphenous vein (GSV) remains the standard for revascularization in CLTI. However, alternative conduits such as autologous arm vein (AAV) and nonautologous biologic (cryovein) were infrequently used in the trial. Using data from the Vascular Quality Initiative, this study examined the outcomes of patients with DM undergoing infrainguinal bypass with AAV and cryovein for CLTI. METHODS: The prospectively collected Vascular Quality Initiative database was retrospectively queried for all patients with DM undergoing infrainguinal bypass for CLTI between 2010 and 2023. Patients were stratified into three cohorts according to the type of graft they received. Baseline characteristics and outcomes for the AAV and cryovein cohorts were compared individually with the GSV group. The primary outcome was amputation-free survival; long-term freedom from index limb reintervention and freedom from major adverse limb events (MALEs) were analyzed as secondary outcomes. RESULTS: Of 17,701 patients with DM undergoing bypass, 87.0% (n = 15,393) received a GSV, 3.5% (n = 616) received an AAV, and 9.6% (n = 1692) received a cryovein. There was no difference in perioperative mortality and early thrombosis between the AAV and GSV groups. Patients in the cryovein cohort, however, demonstrated significantly higher rates of perioperative graft occlusion (3.8% vs 1.5%; P < .001) and major amputation (4.1% vs 1.9%; P < .001) compared with GSV patients, with no difference in mortality. Kaplan-Meier analyses demonstrate that amputation-free survival rates at 5 years were lower for patients receiving cryovein as compared with those receiving GSV (55.8% vs 70.4%; P < .001). Patients receiving AAV exhibited similar rates of amputation-free survival (69.0% vs 70.4%; P = .9) and freedom from MALEs (66.4% vs 68.4%; P = .5) compared with GSV patients at 5 years, whereas cryovein patients experienced significantly more MALEs (55.0% vs 68.4%; P < .001). After multivariate regression analysis, cryovein was independently associated with increased amputation or death (hazard ratio, 1.64; 95% confidence interval, 1.4-1.8) when compared with GSV, whereas AAV demonstrated no difference (hazard ratio, 0.91; 95% confidence interval, 0.7-1.1). CONCLUSIONS: AAV is an effective alternative conduit to GSV in patients with DM undergoing infrainguinal bypass for CLTI. Cryovein has inferior outcomes to GSV, but seems to offer acceptable limb salvage in patients with no other options for conduit.
引用
- Williams ZE, Pinto-Rodriguez P, Zwibelman H, et al. Infrainguinal bypass with alternative conduits in diabetic patients with chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 41654038. doi:10.1016/j.jvs.2026.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。